$1M Preferred Stock Deal Closes for Pulmatrix, Advancing Planned Merger with Eos
Summary
Pulmatrix announced the closing of a $1 million private placement of Series B Convertible Preferred Stock with an affiliate of Eos SENOLYTIX, Inc. This financing is a critical step in the company's planned merger with Eos. The Series B Preferred Stock is convertible into common stock at a price of $2.20 per share, which is above Pulmatrix's current trading price. The proceeds will be used for working capital and general corporate purposes, providing essential capital for the small biopharmaceutical company. This closing signals concrete progress towards the transformative merger, which is expected to significantly alter Pulmatrix's strategic direction and pipeline. Investors should monitor further announcements regarding the definitive merger agreement and its anticipated completion.
At the time of this announcement, PULM was trading at $1.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9M. The 52-week trading range was $1.16 to $9.37. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.